0.6917
3.25%
-0.0232
Pre-market:
.6515
-0.0402
-5.81%
Atara Biotherapeutics Inc stock is currently priced at $0.6917, with a 24-hour trading volume of 819.46K.
It has seen a -3.25% decreased in the last 24 hours and a +16.13% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.7069 pivot point. If it approaches the $0.6838 support level, significant changes may occur.
Atara Biotherapeutics Inc Stock (ATRA) Financials Data
Atara Biotherapeutics Inc (ATRA) Revenue 2024
ATRA reported a revenue (TTM) of $4.54 million for the quarter ending September 30, 2023, a -93.59% decline year-over-year.
Atara Biotherapeutics Inc (ATRA) Net Income 2024
ATRA net income (TTM) was -$290.25 million for the quarter ending September 30, 2023, a -17.47% decrease year-over-year.
Atara Biotherapeutics Inc (ATRA) Cash Flow 2024
ATRA recorded a free cash flow (TTM) of -$200.67 million for the quarter ending September 30, 2023, a +21.13% increase year-over-year.
Atara Biotherapeutics Inc (ATRA) Earnings per Share 2024
ATRA earnings per share (TTM) was -$2.78 for the quarter ending September 30, 2023, a -12.55% decline year-over-year.
Atara Biotherapeutics Inc Stock (ATRA) Latest News
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Why 4D Molecular Therapeutics Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
Benzinga
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Why Rocket Lab Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Benzinga
Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why
Zacks Investment Research
About Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. It is also developing ATA188 and autologous ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product to treat Wilms tumor 1; and ATA230, which is Phase II clinical trials for refractory cytomegalovirus. In addition, the company is developing ATA368 that is under preclinical development for HIV and cancers. It has license agreements with Memorial Sloan Kettering Cancer Center and Amgen, Inc.; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with Moffitt Cancer Center. The company was founded in 2012 and is headquartered in South San Francisco, California.
Cap:
|
Volume (24h):